The classic cholesterol measure — informative but inferior to ApoB for particle-count-driven risk assessment.
LDL-C measures the total cholesterol content of LDL particles. It's the traditional cardiovascular marker and remains widely used, though the field has shifted toward ApoB as a more accurate measure of atherogenic risk — LDL-C can undercount risk in people with small-dense LDL particles (where cholesterol per particle is lower than average).
For most patients, LDL-C and ApoB tell the same story. Divergence (elevated ApoB with "acceptable" LDL-C) indicates small-dense-LDL pattern and warrants ApoB-primary management. Always pair LDL-C with ApoB when possible.
LDL-C is influenced by: dietary saturated fat and cholesterol, genetics (FH, ApoE status), thyroid function, liver function, exercise, body composition, and pharmacologic agents — statins, PCSK9i, bempedoic acid, ezetimibe, GLP-1s.
On GLP-1 therapy, expect LDL-C to drop 10–25% at maintenance dose. On growth hormone protocols (tesamorelin, HGH), LDL-C typically doesn't change dramatically — track ApoB instead. Always check LDL-C alongside ApoB, Lp(a), HDL-C, and triglycerides for full lipidology.
Upload any lab PDF and MyProtocolStack maps your values to LDL-C and 40+ other biomarkers. StackAI interprets the trend in context of your protocol.
Start tracking →Informational only — not medical advice. Reference ranges vary by lab and individual context. Work with a licensed provider to interpret your specific results.